CRT slides: Data and safety monitoring boards—friend or foe to CV trials?

Justine Varieur Cadet | | Cardiovascular Business | Patient Care

WASHINGTON, D.C.—Independent data and safety monitoring boards are a necessary component of any cardiovascular trial involving human participants, but they have received a great deal of scrutiny due to some controversies about decision-making. Ajay J. Kirtane, MD, explained the legal role and responsibilities of these powerful oversight arms of trials.  

About the presenter:

Kirtane is the chief academic officer and director of the interventional cardiology fellowship program at Columbia University Medical Center/NewYork-Presbyterian Hospital in New York City.

Justine Varieur Cadet

Related Content

Early pregnancy blood pressure patterns tied to hypertension risk years later
Enabling X-ray-free ablation procedures in the EP lab
Detecting coronary inflammation on CT imaging could reshape preventive cardiology
Know your options: What cardiologists recommend when alternative access is required for TAVR
New drug therapies targeting Lp(a) could be a breakthrough in cardiovascular care
Getinge ending production of cardiopulmonary surgical perfusion systems

Around the web

Radiology Business
The impact of Trump tariffs on iodine contrast media costs

GE HealthCare said the price of iodine contrast increased by more than 200% between 2017 to 2023. Will new Chinese tariffs drive costs even higher?

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.